|
|
 |
Key Data
|
(m
€) |
|
2005 |
2006 |
2007 |
2008 |
2009 |
| Net Sales |
576.1
(100%) |
576.2
(100%) |
628.4
(100%) |
689.6
(100%) |
747.5
(100%) |
| Operating Income |
111.1
(19.3%) |
120.3
(20.9%) |
131.5
(20.9%) |
144.7
(21.0%) |
162.2
(21.7%) |
| Net Income |
64.5
(11.2%) |
74.0
(12.8%) |
84.9
(13.5%) |
100.4
(14.6%) |
110.6
(14.8%) |

Net Sales

Sales by Business

Pharmaceuticals: Net Sales

Key P&L and Cash Flow
|
(m
€) |
|
2005 |
2006 |
2007 |
2008 |
2009 |
| Net Sales |
576.1 |
576.2 |
628.4 |
689.6 |
747.5 |
Gross profit
as % of Sales |
375.5
65.2% |
384.2
66.7% |
422.1
67.2% |
467.4
67,8% |
511.9
68,5% |
Operating Income
(EBIT) as % of Sales |
111.1
19.3% |
120.3
20.9% |
131.5
20.9% |
144.7
21.0% |
162.2
21.7% |
| Pretax Income |
107.0 |
118.2 |
127.4 |
138.1 |
152.7 |
| Net Income |
64.5 |
74.0 |
84.9 |
100.4 |
110.6 |
| CASH FLOW |
89.0 |
97.3 |
113.7 |
140.3 |
149.2 |

Balance Sheet Structure


Per Share Data
|
2005 |
2006 |
2007 |
2008 |
2009 |
| Earnings per share (EPS) |
0.326 |
0.370 |
0.427 |
0.511 |
0.561 |
| Shareholders'equity per share |
1.621 |
1.836 |
1.989 |
2.262 |
2.575 |
|
 |
|